AB Science S.A. (0Q77.L)
EUR 1.5
(3.89%)
EUR 1.5
(3.89%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 970 Thousand EUR | 1.25% |
| 2022 | 958 Thousand EUR | -40.39% |
| 2021 | 1.6 Million EUR | 1.52% |
| 2020 | 1.58 Million EUR | 0.76% |
| 2019 | 1.57 Million EUR | -7.64% |
| 2018 | 1.7 Million EUR | -2.19% |
| 2017 | 1.73 Million EUR | 15.32% |
| 2016 | 1.5 Million EUR | -33.98% |
| 2015 | 2.28 Million EUR | 8.81% |
| 2014 | 2.09 Million EUR | 8.59% |
| 2013 | 1.93 Million EUR | 44.25% |
| 2012 | 1.34 Million EUR | 21.38% |
| 2011 | 1.1 Million EUR | 20.39% |
| 2010 | 917 Thousand EUR | 190.19% |
| 2009 | 316 Thousand EUR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 560 Thousand EUR | 0.0% |
| 2023 Q3 | 261 Thousand EUR | -41.74% |
| 2023 Q4 | 261 Thousand EUR | 0.0% |
| 2023 FY | 970 Thousand EUR | 1.25% |
| 2023 Q1 | 224 Thousand EUR | -31.91% |
| 2023 Q2 | 448 Thousand EUR | 100.0% |
| 2022 Q3 | 164.5 Thousand EUR | -73.85% |
| 2022 Q2 | 629 Thousand EUR | 100.0% |
| 2022 Q1 | 314.5 Thousand EUR | -60.14% |
| 2022 FY | 958 Thousand EUR | -40.39% |
| 2022 Q4 | 329 Thousand EUR | 100.0% |
| 2021 Q2 | 818 Thousand EUR | 100.0% |
| 2021 Q1 | 409 Thousand EUR | -47.29% |
| 2021 FY | 1.6 Million EUR | 1.52% |
| 2021 Q4 | 789 Thousand EUR | 100.0% |
| 2021 Q3 | 394.5 Thousand EUR | -51.77% |
| 2020 Q2 | 807 Thousand EUR | 100.0% |
| 2020 Q3 | 388 Thousand EUR | -51.92% |
| 2020 FY | 1.58 Million EUR | 0.76% |
| 2020 Q1 | 403.5 Thousand EUR | -48.27% |
| 2020 Q4 | 776 Thousand EUR | 100.0% |
| 2019 Q2 | 791 Thousand EUR | 100.0% |
| 2019 FY | 1.57 Million EUR | -7.64% |
| 2019 Q1 | 395.5 Thousand EUR | -4.58% |
| 2019 Q4 | 780 Thousand EUR | 100.0% |
| 2019 Q3 | 390 Thousand EUR | -50.7% |
| 2018 Q2 | 436 Thousand EUR | 0.0% |
| 2018 Q1 | 436 Thousand EUR | -2.79% |
| 2018 FY | 1.7 Million EUR | -2.19% |
| 2018 Q4 | 414.5 Thousand EUR | 0.0% |
| 2018 Q3 | 414.5 Thousand EUR | -4.93% |
| 2017 FY | 1.73 Million EUR | 15.32% |
| 2017 Q4 | 448.5 Thousand EUR | 0.0% |
| 2017 Q1 | 421 Thousand EUR | 14.4% |
| 2017 Q2 | 421 Thousand EUR | 0.0% |
| 2017 Q3 | 448.5 Thousand EUR | 6.53% |
| 2016 Q4 | 368 Thousand EUR | 0.0% |
| 2016 Q3 | 368 Thousand EUR | -4.66% |
| 2016 Q1 | 386 Thousand EUR | -24.61% |
| 2016 FY | 1.5 Million EUR | -33.98% |
| 2016 Q2 | 386 Thousand EUR | 0.0% |
| 2015 FY | 2.28 Million EUR | 8.81% |
| 2015 Q2 | 630 Thousand EUR | 0.0% |
| 2015 Q4 | 512 Thousand EUR | 0.0% |
| 2015 Q3 | 512 Thousand EUR | -18.73% |
| 2015 Q1 | 630 Thousand EUR | 17.1% |
| 2014 Q4 | 538 Thousand EUR | 0.0% |
| 2014 FY | 2.09 Million EUR | 8.59% |
| 2014 Q1 | 511.49 Thousand EUR | 9.06% |
| 2014 Q2 | 511.49 Thousand EUR | 0.0% |
| 2014 Q3 | 538 Thousand EUR | 5.18% |
| 2013 Q2 | 497.5 Thousand EUR | 0.0% |
| 2013 Q3 | 469 Thousand EUR | -5.73% |
| 2013 Q4 | 469 Thousand EUR | 0.0% |
| 2013 FY | 1.93 Million EUR | 44.25% |
| 2013 Q1 | 497.5 Thousand EUR | 0.0% |
| 2012 FY | 1.34 Million EUR | 21.38% |
| 2011 FY | 1.1 Million EUR | 20.39% |
| 2010 FY | 917 Thousand EUR | 190.19% |
| 2009 FY | 316 Thousand EUR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Boiron SA | 493.24 Million EUR | 99.803% |
| Laboratorios Farmaceuticos Rovi, S.A. | 829.5 Million EUR | 99.883% |
| Vetoquinol SA | 529.27 Million EUR | 99.817% |
| Valneva SE | 153.71 Million EUR | 99.369% |
| Nanobiotix S.A. | 30.05 Million EUR | 96.773% |
| PHAXIAM Therapeutics S.A. | 1.32 Million EUR | 26.848% |
| Vivoryon Therapeutics N.V. | -3.62 Million EUR | 126.796% |
| BioSenic S.A. | 543 Thousand EUR | -78.637% |
| ABIVAX Société Anonyme | 4.62 Million EUR | 79.009% |
| Formycon AG | 77.69 Million EUR | 98.752% |